A Phase 3 interventional study of Donepezil 5 mg and Donepezil 10 mg in Dementia With Lewy Bodies (DLB), sponsored by Eisai Co., Ltd.. Completed at 56 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-06-29.
Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).
This 52-week study consisted of 16-week randomized placebo-controlled (RCT, including 12-week Confirmatory Phase) and 36-week open-label extension phases. Of 142 DLB patients enrolled in the RCT phase (three arms: placebo, 5 mg, and 10 mg), 110 entered the extension phase. The placebo group of the RCT phase initiated active treatment at week 16, and the active groups maintained allocated treatment and dosages until week 24. After week 24, all patients received 10 mg. Dose reduction to 5 mg for safety concerns was allowed.
239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.
This study's enrollment of 142 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.
Browse Lewy Body Disease studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
Drug: Donepezil matched placebo
Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
Drug: Donepezil 5 mg
Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
Drug: Donepezil 10 mg
Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
Drug: Donepezil 10 mg
Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
Drug: Donepezil 10 mg
Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
Also known as: E2020
Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
Also known as: E2020
Change From Baseline in Mini-Mental State Examination (MMSE) Score
The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. Data are presented as change from baseline in mean MMSE +/- standard deviation.
Time frame: Week 12 for Confirmatory Phase
Change From Baseline in Neuropsychiatric Inventory (NPI-2) Score
The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, supplemented by 2 dementia with Lewy bodies (DLB)-relevant domains of sleep, and cognitive fluctuation \[reported as cognitive fluctuation inventory\]) were assessed. The score of each item was calculated as frequency (scale: 1=occasionally to 4=very frequently) x Severity (scale: 1=Mild to 3=Severe). The NPI-2 was calculated as the sum of the scores for hallucinations and cognitive fluctuation, to yield a possible total score of 0 to 24. Lower score=less severity. A negative change score from baseline indicated improvement. Data are presented as change from baseline in mean NPI-2 +/- standard deviation.
Time frame: Week 12 for Confirmatory Phase
| Milestone | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Placebo to Donepezil (5 +10 mg) - Extension Phase | Donepezil (5 +10 mg) - Extension Phase |
|---|---|---|---|---|---|
| Started | 46 | 47 | 49 | 0 | 0 |
| Completed | 37 | 31 | 43 | 0 | 0 |
| Not completed | 9 | 16 | 6 | 0 | 0 |
| Withdrew: Adverse event | 5 | 10 | 1 | 0 | 0 |
| Withdrew: Participant's choice | 3 | 5 | 3 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 2 | 0 | 0 |
| Milestone | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Placebo to Donepezil (5 +10 mg) - Extension Phase | Donepezil (5 +10 mg) - Extension Phase |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 46 | 96 |
| Completed | 0 | 0 | 0 | 34 | 66 |
| Not completed | 0 | 0 | 0 | 12 | 30 |
| Withdrew: Adverse event | 0 | 0 | 0 | 7 | 16 |
| Withdrew: Participant's choice | 0 | 0 | 0 | 4 | 11 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 3 |
The MMSE was used to measure cognitive impairment. The MMSE can evaluate overall cognitive function, and is widely used for the assessment of cognitive impairment in dementia patients. The questionnaire consists of 11 items, and each item aims to evaluate different cognitive domains such as orientation, memory, attention, and construction. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. Data are presented as change from baseline in mean MMSE +/- standard deviation.
| Units on a scale | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase |
|---|---|---|---|
| Change From Baseline in Mini-Mental State Examination (MMSE) Score | 0.6 ± 3.0 | 1.4 ± 3.4 | 2.2 ± 2.9 |
The NPI was a questionnaire that quantified psychiatric symptoms and behavioral disorders in dementia. A total of 12 items (the original NPI-10 consisting of 10 behavioral domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor behavior, supplemented by 2 dementia with Lewy bodies (DLB)-relevant domains of sleep, and cognitive fluctuation \[reported as cognitive fluctuation inventory\]) were assessed. The score of each item was calculated as frequency (scale: 1=occasionally to 4=very frequently) x Severity (scale: 1=Mild to 3=Severe). The NPI-2 was calculated as the sum of the scores for hallucinations and cognitive fluctuation, to yield a possible total score of 0 to 24. Lower score=less severity. A negative change score from baseline indicated improvement. Data are presented as change from baseline in mean NPI-2 +/- standard deviation.
| Units on a scale | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase |
|---|---|---|---|
| Change From Baseline in Neuropsychiatric Inventory (NPI-2) Score | -2.0 ± 4.2 | -1.7 ± 4.3 | -2.9 ± 4.7 |
Collected over For each patient from first dose of study drug administration up to 30 days from last dose of study drug or up to approximately Week 12 for Confirmatory Phase and Week 52 for Extension Phase. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Confirmatory Phase | — | 5/46 (10.9%) | 23/46 (50%) |
| Donepezil 5 mg - Confirmatory Phase | — | 4/47 (8.5%) | 18/47 (38.3%) |
| Donepezil 10 mg - Confirmatory Phase | — | 1/49 (2%) | 17/49 (34.7%) |
| Placebo to Donepezil (5 +10 mg) - Extension Phase | — | 9/37 (24.3%) | 31/37 (83.8%) |
| Donepezil (5 +10 mg) - Extension Phase | — | 12/96 (12.5%) | 62/96 (64.6%) |
| Event | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Placebo to Donepezil (5 +10 mg) - Extension Phase | Donepezil (5 +10 mg) - Extension Phase |
|---|---|---|---|---|---|
| Spinal compression fractureInjury, poisoning and procedural complications | 1/46 | 0/47 | 0/49 | 2/37 | 0/96 |
| Myocardial infarctionCardiac disorders | 1/46 | 0/47 | 0/49 | 1/37 | 0/96 |
| CataractEye disorders | 0/46 | 0/47 | 0/49 | 1/37 | 0/96 |
| Inguinal herniaGastrointestinal disorders | 1/46 | 0/47 | 0/49 | 1/37 | 0/96 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/46 | 0/47 | 0/49 | 1/37 | 0/96 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/46 | 0/47 | 0/49 | 1/37 | 0/96 |
| Loss of consciousnessNervous system disorders | 0/46 | 0/47 | 0/49 | 1/37 | 1/96 |
| AsphyxiaRespiratory, thoracic and mediastinal disorders | 0/46 | 0/47 | 0/49 | 1/37 | 0/96 |
| NauseaGastrointestinal disorders | 0/46 | 1/47 | 0/49 | 0/37 | 1/96 |
| PneumoniaInfections and infestations | 0/46 | 1/47 | 0/49 | 0/37 | 2/96 |
| Event | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Placebo to Donepezil (5 +10 mg) - Extension Phase | Donepezil (5 +10 mg) - Extension Phase |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/46 | 4/47 | 2/49 | 18/37 | 17/96 |
| ContusionInjury, poisoning and procedural complications | 4/46 | 0/47 | 1/49 | 6/37 | 7/96 |
| ParkinsonismNervous system disorders | 2/46 | 2/47 | 4/49 | 5/37 | 12/96 |
| DiarrhoeaGastrointestinal disorders | 2/46 | 1/47 | 1/49 | 4/37 | 6/96 |
| EczemaSkin and subcutaneous tissue disorders | 2/46 | 0/47 | 0/49 | 4/37 | 1/96 |
| ConstipationGastrointestinal disorders | 0/46 | 0/47 | 0/49 | 3/37 | 5/96 |
| NauseaGastrointestinal disorders | 1/46 | 2/47 | 1/49 | 3/37 | 4/96 |
| Hepatic function abnormalHepatobiliary disorders | 2/46 | 0/47 | 0/49 | 3/37 | 0/96 |
| DizzinessNervous system disorders | 0/46 | 0/47 | 0/49 | 3/37 | 1/96 |
| Sleep disorderPsychiatric disorders | 2/46 | 1/47 | 0/49 | 3/37 | 1/96 |
The data is based on Full Analysis Set, defined as all the randomized patients who received the study drug at least once and had valid efficacy assessment data at more than one point.
| Age, Continuous(Years) | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Total |
|---|---|---|---|---|
| Mean | 77.2 ± 6.1 | 78.8 ± 5.1 | 77.7 ± 6.8 | 77.9 ± 6.1 |
| Sex: Female, Male(Participants) | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Total |
|---|---|---|---|---|
| Female | 27 | 25 | 28 | 80 |
| Male | 17 | 20 | 21 | 58 |
| Mini-Mental State Examination (MMSE) Score(Unit on a scale) | Placebo - Confirmatory Phase | Donepezil 5 mg - Confirmatory Phase | Donepezil 10 mg - Confirmatory Phase | Total |
|---|---|---|---|---|
| Mean | 20.3 ± 4.2 | 20.6 ± 4.1 | 20.3 ± 4.8 | 20.4 ± 4.3 |
The record gives a start of Feb 2011, a primary completion of Mar 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil